Cargando…
Advances in the understanding and management of T-cell prolymphocytic leukemia
T-prolymphocytic leukemia (T-PLL) is a rare T-cell neoplasm with an aggressive clinical course. Leukemic T-cells exhibit a post-thymic T-cell phenotype (Tdt(−), CD1a(−), CD5(+), CD2(+) and CD7(+)) and are generally CD4(+)/CD8(−), but CD4(+)/CD8(+) or CD8(+)/CD4(−) T-PLL have also been reported. The...
Autores principales: | Laribi, Kamel, Lemaire, Pierre, Sandrini, Jeremy, Baugier de Materre, Alix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732835/ https://www.ncbi.nlm.nih.gov/pubmed/29262669 http://dx.doi.org/10.18632/oncotarget.22272 |
Ejemplares similares
-
Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022) -
Quadri‐lineage disease involving nodal B‐cell marginal zone lymphoma, high‐grade B‐cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia
por: Laribi, Kamel, et al.
Publicado: (2015) -
Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
por: Laribi, Kamel, et al.
Publicado: (2019) -
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
por: Varadarajan, Indumathy, et al.
Publicado: (2022) -
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment
por: Gutierrez, Marc, et al.
Publicado: (2023)